80 FR 71816 - National Institute of Allergy and Infectious Diseases: Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 80, Issue 221 (November 17, 2015)

Page Range		71816-71816
FR Document		2015-29247

Federal Register, Volume 80 Issue 221 (Tuesday, November 17, 2015)

[Federal Register Volume 80, Number 221 (Tuesday, November 17, 2015)]
[Notices]
[Page 71816]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-29247]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases: Notice of 
Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; NIAID SBIR Phase II Clinical Trial 
Implementation Cooperative Agreement (U44).
    Date: December 9, 2015.
    Time: 9:00 a.m. to 2:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Room 4C100, 5601 Fishers 
Lane, Rockville, MD 20892.
    Contact Person: Zhuqing (Charlie) Li, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, Room # 3G41B, National Institutes of Health/NIAID, 5601 
Fishers Lane, MSC9823, Bethesda, MD 20892-9823, (240) 669-5068, 
[email protected].

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; NIAID Resource-Related Research 
Projects (R24) and NIAID Investigator Initiated Program Project 
Applications (P01).
    Date: January 12-13, 2016.
    Time: 12:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Room 3F100, 5601 Fishers 
Lane, Rockville, MD 20892 (Telephone Conference Call).
    Contact Person: Quirijn Vos, Ph.D., Scientific Review Officer, 
Scientific Review Program, Division of Extramural Activities, Room 
3G31A, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC 
9823, Bethesda, MD 20892-9823, (240) 669-5059, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: November 9, 2015.
Natasha Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-29247 Filed 11-16-15; 8:45 am]
 BILLING CODE 4140-01-P

71816 Federal Register / Vol. 80, No. 221 / Tuesday, November 17, 2015 / Notices

TABLE 1—ESTIMATES OF ANNUAL BURDEN
Average time
Number of Frequency of Total hour
Type of respondents Form per response
respondents response burden
(in hours)

Investigators and Designee for In- Statement of Investigator (Attach- 22,283 1 15/60 5,571
vestigator Registration and DARF. ments 3A, 3B or 10).
NCI/DCTD/CTEP Supplemental In- 22,283 1 10/60 3,721
vestigator (Attachment 4).
Financial Disclosure Forms (Attach- 22,283 1 5/60 1,849
ment 5A or 5B).
NCI/DCTD/CTEP Drug Account- 3,288 16 4/60 3,525
ability Record Form (DARF and
DARF-Oral) (Attachments 1 & 2).

Dated: November 9, 2015. Emphasis Panel; NIAID Resource-Related decide whether NCI should support
Karla Bailey, Research Projects (R24) and NIAID requests and make available contract
Investigator Initiated Program Project resources for development of the
Project Clearance Liaison, National Cancer
Applications (P01).
Institute, NIH. potential therapeutic to improve the
Date: January 12–13, 2016.
[FR Doc. 2015–29246 Filed 11–16–15; 8:45 am] Time: 12:00 p.m. to 5:00 p.m. treatment of various forms of cancer.
BILLING CODE 4140–01–P Agenda: To review and evaluate grant The research proposals and the
applications. discussions could disclose confidential
Place: National Institutes of Health, Room trade secrets or commercial property
DEPARTMENT OF HEALTH AND 3F100, 5601 Fishers Lane, Rockville, MD such as patentable material, and
HUMAN SERVICES 20892 (Telephone Conference Call). personal information concerning
Contact Person: Quirijn Vos, Ph.D., individuals associated with the
National Institutes of Health Scientific Review Officer, Scientific Review
proposed research projects, the
Program, Division of Extramural Activities,
Room 3G31A, National Institutes of Health/ disclosure of which would constitute a
National Institute of Allergy and clearly unwarranted invasion of
Infectious Diseases: Notice of Closed NIAID, 5601 Fishers Lane, MSC 9823,
Bethesda, MD 20892–9823, (240) 669–5059, personal privacy.
Meetings qvos@niaid.nih.gov. Name of Committee: National Cancer
Pursuant to section 10(d) of the (Catalogue of Federal Domestic Assistance Institute Special Emphasis Panel; Dec 2015
Federal Advisory Committee Act, as Program Nos. 93.855, Allergy, Immunology, Cycle 21 NExT SEP Committee Meeting.
amended (5 U.S.C. App.), notice is and Transplantation Research; 93.856, Date: December 16, 2015.
hereby given of the following meetings. Microbiology and Infectious Diseases Time: 8:30 a.m. to 4:30 p.m.
The meetings will be closed to the Research, National Institutes of Health, HHS) Agenda: To evaluate the NCI Experimental
public in accordance with the Dated: November 9, 2015. Therapeutics Program Portfolio.
provisions set forth in sections Natasha Copeland, Place: National Institutes of Health, 9000
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Rockville Pike, Campus Building 31,
Program Analyst, Office of Federal Advisory
as amended. The grant applications and Conference Room 6C6, Bethesda, MD 20892.
Committee Policy.
the discussions could disclose Contact Person: Barbara Mroczkowski,
[FR Doc. 2015–29247 Filed 11–16–15; 8:45 am] Ph.D., Executive Secretary, Discovery
confidential trade secrets or commercial
property such as patentable material,
BILLING CODE 4140–01–P Experimental Therapeutics Program National
Cancer Institute, NIH, 31 Center Drive, Room
and personal information concerning
3A44, Bethesda, MD 20817, (301) 496–4291,
individuals associated with the grant DEPARTMENT OF HEALTH AND mroczkoskib@mail.nih.gov.
applications, the disclosure of which HUMAN SERVICES Toby Hecht, Ph.D., Executive Secretary,
would constitute a clearly unwarranted Development Experimental Therapeutics
invasion of personal privacy. National Institutes of Health Program, National Cancer Institute, NIH,
Name of Committee: National Institute of 9609 Medical Center Drive, Room 3W110,
Allergy and Infectious Diseases Special National Cancer Institute; Notice of Rockville, MD 20850, (240) 276–5683
Emphasis Panel; NIAID SBIR Phase II Closed Meeting toby.hecht2@nih.gov.
Clinical Trial Implementation Cooperative (Catalogue of Federal Domestic Assistance
Agreement (U44). Pursuant to section 10(d) of the
Federal Advisory Committee Act, as Program Nos. 93.392, Cancer Construction;
Date: December 9, 2015. 93.393, Cancer Cause and Prevention
Time: 9:00 a.m. to 2:00 p.m. amended (5 U.S.C. Appendix 2); notice
Research; 93.394, Cancer Detection and
Agenda: To review and evaluate grant is hereby given of the following
Diagnosis Research; 93.395, Cancer
applications. meeting.
Treatment Research; 93.396, Cancer Biology
Place: National Institutes of Health, Room The meeting will be closed to the
4C100, 5601 Fishers Lane, Rockville, MD Research; 93.397, Cancer Centers Support;
public in accordance with the 93.398, Cancer Research Manpower; 93.399,
20892. provisions set forth in sections
Contact Person: Zhuqing (Charlie) Li, Cancer Control, National Institutes of Health,
mstockstill on DSK4VPTVN1PROD with NOTICES

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., HHS)
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural as amended. The purpose of this
meeting is to evaluate requests for Dated: November 10, 2015.
Activities, Room # 3G41B, National Institutes
preclinical development resources for Melanie J. Gray,
of Health/NIAID, 5601 Fishers Lane,
MSC9823, Bethesda, MD 20892–9823, (240) potential new therapeutics for the Program Analyst, Office of Federal Advisory
669–5068, zhuqing.li@nih.gov. treatment of cancer. The outcome of the Committee Policy.
Name of Committee: National Institute of evaluation will provide information to [FR Doc. 2015–29245 Filed 11–16–15; 8:45 am]
Allergy and Infectious Diseases Special internal NCI committees that will BILLING CODE 4140–01–P

VerDate Sep<11>2014 18:14 Nov 16, 2015 Jkt 238001 PO 00000 Frm 00047 Fmt 4703 Sfmt 9990 E:\FR\FM\17NON1.SGM 17NON1

Document Created: 2015-12-14 14:00:08
Document Modified: 2015-12-14 14:00:08

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		December 9, 2015.
FR Citation		80 FR 71816

80 FR 71816 - National Institute of Allergy and Infectious Diseases: Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 80, Issue 221 (November 17, 2015)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health